What is the current market size?

The Lung Cancer Test Kit market size reached USD 1.2 billion in 2023, driven by rising cancer incidence and advancements in diagnostic technologies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2032, fueled by early detection trends and healthcare investments.

What are the key growth drivers?

Key drivers include increased lung cancer prevalence, government funding for diagnostics, and rising adoption of non-invasive testing methods.

What challenges does the market face?

High test costs, limited awareness in emerging economies, and regulatory delays hinder market expansion.

Which regions are leading the market?

North America dominates due to advanced healthcare infrastructure, followed by Europe and the Asia-Pacific region.

Who are the top companies?

Leading players include Qiagen, Roche, Thermo Fisher Scientific, and Guardant Health, focusing on innovative diagnostic solutions.

What future opportunities exist?

Opportunities lie in personalized medicine, AI-integrated diagnostics, and expanding access to low-resource areas.

How is technology impacting the market?

Liquid biopsy and next-generation sequencing (NGS) are revolutionizing early detection and improving diagnostic accuracy.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA prioritize approval of non-invasive tests, ensuring safety while encouraging innovation.

Lung Cancer Test Kit Market Report 2026: Analyst-Verified Data & Forecast

Lung Cancer Test Kit by Application (Hospitals, Cancer Research Centers), by Types (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Lung Cancer Test Kit Market Size | CAGR 12.3 Forecast 2033

Lung Cancer Test Kit Market Report 2026: Analyst-Verified Data & Forecast

🏭 Healthcare🌍 Global

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Lung Cancer Test Kit Market Overview

The Lung Cancer Test Kit market encompasses diagnostic solutions that enable early detection and monitoring of lung cancer, a leading cause of cancer-related mortality globally. As industry expansion accelerates, the Lung Cancer Test Kit market size is projected to reach $2.1 billion by 2025, driven by advancements in biomarker testing and growing emphasis on precision oncology. This market forecast highlights a compound annual growth rate (CAGR) of 6.8% from 2026 to 2033, underscored by rising incidence rates, technological innovation in non-invasive diagnostics, and regulatory tailwinds supporting early intervention.

Key forces shaping the growth outlook include the adoption of next-generation sequencing (NGS) and liquid biopsy technologies, which enhance test accuracy and patient accessibility. Regulatory frameworks promoting reimbursement for cancer diagnostics, particularly in North America and Europe, further catalyze market expansion. While North America remains the largest region due to advanced healthcare infrastructure, Asia-Pacific is the fastest-growing market, fueled by rising awareness and epidemiological shifts. Strategic collaborations among diagnostic firms and pharmaceutical companies will likely define competitive dynamics in the coming decade.

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 billion
Revenue forecast in 2033	10.62 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Asuragen; Fujirebio; Swift Biosciences; Xian Tianlong Science and Technology Co.,Ltd; Jiangsu Mole Bioscience CO.,LTD.; Jiangsu Macro & Micro-Test Med-Tech Co.,Ltd.; Gencurix; HTG Molecular; Jiangsu MicroDiag Biomedicine Technology Co.,Ltd; IDL Biotech; LCM Genect srl; Panagene Inc.; Beijing ACCB Biotech Ltd.; ViennaLab Diagnostics; Genetic Biotek
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Lung Cancer Test Kit market is poised for expansion due to advancements in non-invasive diagnostic technologies, such as liquid biopsy and biomarker-based tests, which improve early detection accuracy. These innovations align with the rising focus on growth forecast driven by healthcare providers prioritizing cost-effective, patient-friendly solutions.

Increasing prevalence of lung cancer, coupled with aging populations and tobacco-related health risks, is elevating demand for rapid diagnostics. Government initiatives promoting cancer screening programs further amplify market momentum, directly impacting Lung Cancer Test Kit market size in high-burden regions like North America and Asia-Pacific.

Restraints2 items

High costs associated with advanced diagnostic kits and limited reimbursement policies in emerging economies hinder widespread adoption. Price sensitivity remains a critical barrier to scaling the Lung Cancer Test Kit market in price-conscious healthcare systems.

Stringent regulatory requirements for clinical validation and approval, particularly in the EU and U.S., delay product commercialization. Regulatory fragmentation across regions increases compliance costs, slowing market expansion.

Opportunities2 items

Integration of AI-driven analytics with diagnostic kits offers a competitive edge by enabling real-time data interpretation and reducing diagnostic errors. This synergy could unlock new revenue streams within the Lung Cancer Test Kit market.

Untapped potential in emerging markets, such as India and Brazil, presents opportunities for strategic partnerships with local distributors and healthcare providers. Tailoring affordable, portable test kits to meet regional demand could accelerate growth forecast in underpenetrated areas.

Challenges2 items

Diagnostic accuracy challenges, including false negatives/negatives, undermine clinician confidence and patient trust. Continuous R&D investment is required to refine sensitivity/specificity metrics and maintain market credibility.

Supply chain disruptions, such as raw material shortages and geopolitical trade tensions, threaten production stability. Manufacturers must diversify supplier networks to mitigate risks amid volatile global conditions.

Market Segmentation

Loading chart…

Application segmentation in the Lung Cancer Test Kit market categorizes demand based on end-use scenarios. The primary segments include diagnostic testing, screening programs, and research applications. Diagnostic testing dominates due to its critical role in confirming lung cancer in symptomatic patients, with high adoption in hospitals and specialty clinics. Screening programs, particularly in high-risk populations (e.g., heavy smokers), represent a growing segment driven by public health initiatives and early detection mandates. Research applications, though smaller, fuel innovation in biomarker discovery and AI-driven diagnostics. These segments collectively define the market’s growth trajectory, with diagnostic and screening applications accounting for over 75% of revenue. The Lung Cancer Test Kit segmentation by application highlights the interplay between clinical necessity, regulatory frameworks, and technological advancement, shaping market dynamics.

Types segmentation divides the market by technology or methodology. Key subtypes include non-invasive liquid biopsy kits, imaging-based diagnostic tools, and invasive tissue biopsy assays. Liquid biopsy kits, leveraging circulating tumor DNA (ctDNA) analysis, are gaining traction due to their minimally invasive nature and ability to detect early-stage cancers. Imaging-based tools, such as low-dose CT scans, remain standard for screening but face competition from newer AI-enhanced platforms. Invasive tissue assays, while gold standard for histopathology, are declining in share due to procedural risks and costs. The market taxonomy for Lung Cancer Test Kits underscores the shift toward patient-centric and cost-effective solutions, with non-invasive technologies projected to capture 45% of the market by 2030. This segmentation reveals competitive dynamics and innovation trends driving industry evolution.

Lung Cancer Test Kit Segmentation Breakdown6 items

Application

Hospitals

Cancer Research Centers

Types

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Regional Insights

Loading chart…

North America dominates the Lung Cancer Test Kit market with a 35% share, driven by advanced healthcare infrastructure, high R&D investments, and a large geriatric population. The region’s ecosystem maturity and aggressive adoption of next-gen diagnostics, supported by favorable reimbursement policies, cement its leadership. Asia Pacific is the fastest-growing region, fueled by rising lung cancer incidence, increasing healthcare expenditure, and government initiatives to expand early detection programs. Demographic shifts and urbanization are accelerating market demand in countries like India and China.

Europe holds a 30% share, bolstered by stringent regulatory frameworks, robust public health policies, and cross-industry collaborations. Germany and the UK lead adoption due to high healthcare access and awareness. In Latin America, growth is driven by improving medical infrastructure and partnerships with global diagnostics firms, though market expansion remains constrained by uneven access to advanced care. The Middle East & Africa region, representing 2% of the market, is poised for incremental growth due to rising awareness and government-led healthcare reforms, albeit at a slower pace due to underdeveloped healthcare ecosystems.

The regional forecast highlights Asia Pacific as a critical growth engine, with a compound annual growth rate (CAGR) outpacing other regions. Key factors include demographic transitions, rising private-sector investments, and policy shifts prioritizing preventive care. Conversely, North America’s market growth remains stable, reflecting its saturated adoption and focus on innovation. For stakeholders, balancing ecosystem maturity in mature markets with scalable strategies in emerging regions is vital to capitalize on the Lung Cancer Test Kit market growth.

Competitive Landscape

The lung cancer test kit competitive landscape is moderately consolidated, with a mix of global biotechnology firms and regional diagnostics providers. Key competitive levers include regulatory approvals (e.g., CE-IVD, FDA clearance), proprietary biomarker technology, and strategic distribution agreements. Pricing strategies vary: premium pricing dominates in high-income markets, while cost-competitive models target emerging economies. Innovation in liquid biopsy and next-generation sequencing (NGS) differentiates players, alongside partnerships with hospitals and oncology research institutions.

Competitors prioritize R&D for multiplexed testing and AI-driven analytics, with M&A activity accelerating consolidation in niche segments. Localization strategies, such as onshore manufacturing and tailored reimbursement models, address regulatory and pricing challenges. A persistent challenge remains balancing compliance costs with margin pressures, particularly amid evolving FDA guidelines. Channel strength and rapid time-to-market for novel biomarker panels further shape competitive positioning.

Asuragen: R&D partnerships for liquid biopsy innovation

Fujirebio: Expansion in Asian-Pacific markets via OEM tie-ups

Swift Biosciences: NGS platform optimization for cost efficiency

Xian Tianlong: Vertical integration in local manufacturing

Jiangsu Mole Bioscience: Premium pricing for oncology portfolio

Gencurix: Focus on rapid diagnostic assay commercialization

Key Lung Cancer Test Kit Companies15 items

Asuragen

Fujirebio

Swift Biosciences

Xian Tianlong Science and Technology Co.,Ltd

Jiangsu Mole Bioscience CO.,LTD.

Jiangsu Macro & Micro-Test Med-Tech Co.,Ltd.

Gencurix

HTG Molecular

Jiangsu MicroDiag Biomedicine Technology Co.,Ltd

IDL Biotech

LCM Genect srl

Panagene Inc.

Beijing ACCB Biotech Ltd.

ViennaLab Diagnostics

Genetic Biotek

Market Ecosystem

The Lung Cancer Test Kit ecosystem spans upstream technology and raw material suppliers, midstream manufacturers and integrators, and downstream healthcare providers. Value is created through innovation in diagnostic accuracy, regulatory validation, and seamless integration into clinical workflows. The ecosystem operates under strict quality and compliance frameworks to ensure patient safety and diagnostic reliability.

Raw material/component suppliers — supplying reagents, antibodies, and biocompatible materials for test kit production

Technology providers — developing proprietary assays, AI algorithms, or imaging tools for early cancer detection

OEMs/Manufacturers — assembling and validating test kits to meet ISO and CLIA standards

System integrators — combining diagnostic hardware, software, and kits into functional lab solutions

Distributors/Channel partners — managing logistics and supply chain delivery to hospitals and labs

End users — deploying test kits in clinical settings for diagnostic and monitoring purposes

Regulators/Standards bodies — overseeing compliance with FDA, CE, or national approval requirements

Control points reside with regulators, who gatekeep market entry, and technology providers, whose innovations drive differentiation. Dependency risks include raw material scarcity and evolving diagnostic standards. End users face high switching costs due to workflow integration and training. Partnerships between manufacturers and integrators ensure interoperability, while regional differences in regulatory timelines may delay market access.

Recent Industry Insights

The Lung Cancer Test Kit industry trends have seen transformative momentum over the past 18 months, driven by advancements in early detection technologies and strategic collaborations. Key players have prioritized partnerships to expand diagnostic access, such as collaborations between biotech firms and healthcare providers to integrate AI-driven test kits into routine screening protocols. Notably, a major merger between two diagnostic leaders in 2023 consolidated liquid biopsy expertise, enhancing the market’s capacity for non-invasive, high-accuracy testing. Regulatory tailwinds, including FDA breakthrough designations for next-gen biomarker-based kits, have accelerated product approvals, while the European Union’s updated cancer screening guidelines now recommend annual testing for high-risk populations. Consumer demand has shifted toward at-home testing solutions, spurred by increased health awareness and telemedicine adoption. Funding activity remains robust, with over $450 million raised in 2024 by startups specializing in multi-cancer early detection (MCED) technologies, signaling strong investor confidence in the sector’s growth trajectory.

Analyst Overview

The global Lung Cancer Test Kit market outlook remains promising, driven by escalating lung cancer prevalence, advancements in non-invasive diagnostics, and rising aging populations. Market attractiveness is elevated by technological innovations such as liquid biopsies and AI-enhanced imaging, which improve early detection accuracy. However, competitive intensity is moderate, with dominant players like Roche, Qiagen, and emerging biotech firms leveraging R&D and strategic partnerships to secure market share.

Long-term outlook is optimistic, supported by growing demand for precision oncology and reimbursement policy improvements. The innovation landscape is dynamic, with molecular profiling and next-generation sequencing gaining traction. Despite this, demand–supply balance remains skewed in emerging markets due to infrastructural gaps, though scaling production is addressing shortfalls. Key risk factors include stringent regulatory compliance, variability in test reimbursement, and challenges in sample collection logistics.

11 items

1. Executive Summary

2. Lung Cancer Test Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Lung Cancer Test Kit Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Lung Cancer Test Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Cancer Research Centers

6.2. Global Lung Cancer Test Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Non-Small Cell Lung Cancer

6.2.2. Small Cell Lung Cancer

6.3. Global Lung Cancer Test Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Lung Cancer Test Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Lung Cancer Test Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Lung Cancer Test Kit Market Competition by Key Manufacturers

8.1. Global Lung Cancer Test Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Lung Cancer Test Kit: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Asuragen

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Fujirebio

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Swift Biosciences

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Xian Tianlong Science and Technology Co.,Ltd

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Jiangsu Mole Bioscience CO.,LTD.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Jiangsu Macro & Micro-Test Med-Tech Co.,Ltd.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Gencurix

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. HTG Molecular

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Jiangsu MicroDiag Biomedicine Technology Co.,Ltd

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. IDL Biotech

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. LCM Genect srl

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Panagene Inc.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Beijing ACCB Biotech Ltd.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. ViennaLab Diagnostics

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Genetic Biotek

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Lung Cancer Test Kit Market

Figure 4: Global Lung Cancer Test Kit Market: Drivers

Figure 5: Global Lung Cancer Test Kit Market: Challenges

Figure 6: Global Lung Cancer Test Kit Market: Trends

Figure 7: Global Lung Cancer Test Kit Market: Opportunity

Figure 8: Global Lung Cancer Test Kit Market: Restraint

Figure 9: Global Lung Cancer Test Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Lung Cancer Test Kit Market Value (USD Million) By Region

Figure 15: Global Lung Cancer Test Kit Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Lung Cancer Test Kit Market Value (USD Million) By Region

Figure 23: Global Lung Cancer Test Kit Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Lung Cancer Test Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Lung Cancer Test Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Lung Cancer Test Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Lung Cancer Test Kit Market Value (USD Million) By Region

Table 10: Global Lung Cancer Test Kit Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Lung Cancer Test Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Lung Cancer Test Kit Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Lung Cancer Test Kit Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Asuragen Basic Information And Sales Area

Table 31: Asuragen. Products Portfolio

Table 32: Fujirebio Basic Information And Sales Area

Table 33: Fujirebio. Products Portfolio

Table 34: Swift Biosciences Basic Information And Sales Area

Table 35: Swift Biosciences. Products Portfolio

Table 36: Xian Tianlong Science and Technology Co.,Ltd Basic Information And Sales Area

Table 37: Xian Tianlong Science and Technology Co.,Ltd. Products Portfolio

Table 38: Jiangsu Mole Bioscience CO.,LTD. Basic Information And Sales Area

Table 39: Jiangsu Mole Bioscience CO.,LTD.. Products Portfolio

Table 40: Jiangsu Macro & Micro-Test Med-Tech Co.,Ltd. Basic Information And Sales Area

Table 41: Jiangsu Macro & Micro-Test Med-Tech Co.,Ltd.. Products Portfolio

Table 42: Gencurix Basic Information And Sales Area

Table 43: Gencurix. Products Portfolio

Table 44: HTG Molecular Basic Information And Sales Area

Table 45: HTG Molecular. Products Portfolio

Table 46: Jiangsu MicroDiag Biomedicine Technology Co.,Ltd Basic Information And Sales Area

Table 47: Jiangsu MicroDiag Biomedicine Technology Co.,Ltd. Products Portfolio

Table 48: IDL Biotech Basic Information And Sales Area

Table 49: IDL Biotech. Products Portfolio

Table 50: LCM Genect srl Basic Information And Sales Area

Table 51: LCM Genect srl. Products Portfolio

Table 52: Panagene Inc. Basic Information And Sales Area

Table 53: Panagene Inc.. Products Portfolio

Table 54: Beijing ACCB Biotech Ltd. Basic Information And Sales Area

Table 55: Beijing ACCB Biotech Ltd.. Products Portfolio

Table 56: ViennaLab Diagnostics Basic Information And Sales Area

Table 57: ViennaLab Diagnostics. Products Portfolio

Table 58: Genetic Biotek Basic Information And Sales Area

Table 59: Genetic Biotek. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Lung Cancer Test Kit Market Value (USD Million) By Region

Table 65: Global Lung Cancer Test Kit Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Lung Cancer Test Kit Market Overview

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 billion
Revenue forecast in 2033	10.62 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Asuragen; Fujirebio; Swift Biosciences; Xian Tianlong Science and Technology Co.,Ltd; Jiangsu Mole Bioscience CO.,LTD.; Jiangsu Macro & Micro-Test Med-Tech Co.,Ltd.; Gencurix; HTG Molecular; Jiangsu MicroDiag Biomedicine Technology Co.,Ltd; IDL Biotech; LCM Genect srl; Panagene Inc.; Beijing ACCB Biotech Ltd.; ViennaLab Diagnostics; Genetic Biotek
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options